{"id":49994,"date":"2025-12-04T21:46:32","date_gmt":"2025-12-04T13:46:32","guid":{"rendered":"https:\/\/flcube.com\/?p=49994"},"modified":"2025-12-04T21:46:33","modified_gmt":"2025-12-04T13:46:33","slug":"novo-nordisk-semaglutide-alzheimers-biomarkers-fail-primary-endpoint","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49994","title":{"rendered":"Novo Nordisk semaglutide Alzheimer&#8217;s biomarkers fail primary endpoint"},"content":{"rendered":"\n<p><strong>Novo Nordisk<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) reported at the Clinical Trials on Alzheimer\u2019s Disease conference that <strong>semaglutide<\/strong> failed to slow <strong>Alzheimer\u2019s disease<\/strong> progression in two Phase 3 trials involving over 3,500 patients, though the drug showed modest biomarker improvements that may warrant further investigation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-executive-summary-trial-results-amp-biomarker-data\">Executive Summary: Trial Results &amp; Biomarker Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Outcome Measure<\/th><th>Result<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Failed to slow cognitive progression<\/td><td>No clinical efficacy demonstrated<\/td><\/tr><tr><td><strong>Patient Enrollment<\/strong><\/td><td>&gt;3,500 patients across two trials<\/td><td>Large, adequately powered studies<\/td><\/tr><tr><td><strong>Cognitive Benefit<\/strong><\/td><td>No improvement observed<\/td><td>Trials did not meet objectives<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Under evaluation<\/td><td>Company analyzing subset data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-biomarker-findings-mixed-signals-despite-clinical-failure\">Biomarker Findings: Mixed Signals Despite Clinical Failure<\/h2>\n\n\n\n<p><strong>Positive Signals (10% or less reductions):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Neurodegeneration markers: modest decreases in CSF<\/li>\n\n\n\n<li>Inflammation markers: slight reductions observed<\/li>\n\n\n\n<li>Tau protein deposits: limited reduction in abnormal protein<\/li>\n<\/ul>\n\n\n\n<p><strong>Negative Signals:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Majority of 30 biomarkers: no change detected<\/li>\n\n\n\n<li>Clinical correlation: biomarker improvements did not translate to cognitive benefit<\/li>\n<\/ul>\n\n\n\n<p><strong>Peter Johannsen<\/strong>, Novo\u2019s international medical vice president, stated: &#8220;semaglutide actually does something to biomarkers,&#8221; but emphasized that &#8220;we still think it was the right decision. This was a scientific question that needed an answer, although we didn\u2019t get the answer that we had hoped for.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-alzheimer-s-pipeline\">Strategic Context &amp; Alzheimer\u2019s Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Alzheimer\u2019s Asset<\/th><th>Mechanism<\/th><th>Status<\/th><th>Key Differentiator<\/th><\/tr><\/thead><tbody><tr><td><strong>Semaglutide<\/strong><\/td><td>GLP-1 receptor agonist<\/td><td>Phase 3 failed<\/td><td>Metabolic approach to neurodegeneration<\/td><\/tr><tr><td><strong>Lecanemab<\/strong> (Eisai\/Biogen)<\/td><td>Anti-amyloid antibody<\/td><td>Marketed<\/td><td>Modest clinical benefit<\/td><\/tr><tr><td><strong>Donanemab<\/strong> (Lilly)<\/td><td>Anti-amyloid antibody<\/td><td>Marketed<\/td><td>Similar efficacy to lecanemab<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Market Reality:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>$6 billion<\/strong> global Alzheimer\u2019s therapeutic market<\/li>\n\n\n\n<li><strong>High failure rate<\/strong>: 99% of Alzheimer\u2019s drugs fail in development<\/li>\n\n\n\n<li><strong>Metabolic hypothesis<\/strong>: Novo&#8217;s approach was novel but unproven<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps-amp-decision-making\">Next Steps &amp; Decision Making<\/h2>\n\n\n\n<p><strong>Current Status:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Data analysis ongoing to identify potential responder subpopulations<\/li>\n\n\n\n<li>No commitment to additional trials at this time<\/li>\n\n\n\n<li>Focus on understanding biomarker-clinical disconnect<\/li>\n<\/ul>\n\n\n\n<p><strong>Peter Johannsen on Future:<\/strong> &#8220;We are still digging into the data, and it\u2019s too early to say what its next steps will be.&#8221;<\/p>\n\n\n\n<p><strong>Clinical Implications:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>GLP-1 mechanism may not be sufficient for Alzheimer\u2019s modification<\/li>\n\n\n\n<li>Biomarker improvements without clinical benefit question therapeutic hypothesis<\/li>\n\n\n\n<li>Resources may be redirected to other neurodegeneration programs<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Novo Nordisk&#8217;s potential next steps for semaglutide in Alzheimer\u2019s disease. Actual decisions may differ based on complete data analysis, regulatory feedback, and strategic prioritization of R&amp;D resources. The biomarker findings have not been independently verified.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer\u2019s Disease conference that semaglutide&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49995,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,4361,148,860],"class_list":["post-49994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hot-targets","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk semaglutide Alzheimer&#039;s biomarkers fail primary endpoint - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer\u2019s Disease conference that semaglutide failed to slow Alzheimer\u2019s disease progression in two Phase 3 trials involving over 3,500 patients, though the drug showed modest biomarker improvements that may warrant further investigation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49994\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk semaglutide Alzheimer&#039;s biomarkers fail primary endpoint\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer\u2019s Disease conference that semaglutide failed to slow Alzheimer\u2019s disease progression in two Phase 3 trials involving over 3,500 patients, though the drug showed modest biomarker improvements that may warrant further investigation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49994\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T13:46:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-04T13:46:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49994#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49994\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk semaglutide Alzheimer&#8217;s biomarkers fail primary endpoint\",\"datePublished\":\"2025-12-04T13:46:32+00:00\",\"dateModified\":\"2025-12-04T13:46:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49994\"},\"wordCount\":400,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49994#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0407-1.webp\",\"keywords\":[\"Clinical trial results\",\"Hot targets\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49994#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49994\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49994\",\"name\":\"Novo Nordisk semaglutide Alzheimer's biomarkers fail primary endpoint - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49994#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49994#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0407-1.webp\",\"datePublished\":\"2025-12-04T13:46:32+00:00\",\"dateModified\":\"2025-12-04T13:46:33+00:00\",\"description\":\"Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer\u2019s Disease conference that semaglutide failed to slow Alzheimer\u2019s disease progression in two Phase 3 trials involving over 3,500 patients, though the drug showed modest biomarker improvements that may warrant further investigation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49994#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49994\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49994#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0407-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0407-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk semaglutide Alzheimer's biomarkers fail primary endpoint\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49994#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk semaglutide Alzheimer&#8217;s biomarkers fail primary endpoint\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk semaglutide Alzheimer's biomarkers fail primary endpoint - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer\u2019s Disease conference that semaglutide failed to slow Alzheimer\u2019s disease progression in two Phase 3 trials involving over 3,500 patients, though the drug showed modest biomarker improvements that may warrant further investigation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49994","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk semaglutide Alzheimer's biomarkers fail primary endpoint","og_description":"Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer\u2019s Disease conference that semaglutide failed to slow Alzheimer\u2019s disease progression in two Phase 3 trials involving over 3,500 patients, though the drug showed modest biomarker improvements that may warrant further investigation.","og_url":"https:\/\/flcube.com\/?p=49994","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-04T13:46:32+00:00","article_modified_time":"2025-12-04T13:46:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49994#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49994"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk semaglutide Alzheimer&#8217;s biomarkers fail primary endpoint","datePublished":"2025-12-04T13:46:32+00:00","dateModified":"2025-12-04T13:46:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49994"},"wordCount":400,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49994#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407-1.webp","keywords":["Clinical trial results","Hot targets","Novo Nordisk","NYSE: NVO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49994#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49994","url":"https:\/\/flcube.com\/?p=49994","name":"Novo Nordisk semaglutide Alzheimer's biomarkers fail primary endpoint - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49994#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49994#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407-1.webp","datePublished":"2025-12-04T13:46:32+00:00","dateModified":"2025-12-04T13:46:33+00:00","description":"Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer\u2019s Disease conference that semaglutide failed to slow Alzheimer\u2019s disease progression in two Phase 3 trials involving over 3,500 patients, though the drug showed modest biomarker improvements that may warrant further investigation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49994#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49994"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49994#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407-1.webp","width":1080,"height":608,"caption":"Novo Nordisk semaglutide Alzheimer's biomarkers fail primary endpoint"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49994#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk semaglutide Alzheimer&#8217;s biomarkers fail primary endpoint"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49994"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49994\/revisions"}],"predecessor-version":[{"id":49996,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49994\/revisions\/49996"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49995"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}